Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001628280-25-020467
Filing Date
2025-04-29
Accepted
2025-04-29 07:02:31
Documents
13

Document Format Files

Seq Description Document Type Size
1 DEFA14A cccc-20250429.htm   iXBRL DEFA14A 12475
3 cccc-20250429_g1.jpg GRAPHIC 489877
4 cccc-20250429_g2.jpg GRAPHIC 440817
  Complete submission text file 0001628280-25-020467.txt   2258170

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cccc-20250429.xsd EX-101.SCH 804
15 EXTRACTED XBRL INSTANCE DOCUMENT cccc-20250429_htm.xml XML 954
Mailing Address 490 ARSENAL WAY SUITE 120 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY SUITE 120 WATERTOWN MA 02472 (617) 231-0700
C4 Therapeutics, Inc. (Filer) CIK: 0001662579 (see all company filings)

EIN.: 475617627 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39567 | Film No.: 25882601
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)